Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models.
about
TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in miceStabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?(3)D [corrected] quantification of tumor vasculature in lymphoma xenografts in NOD/SCID mice allows to detect differences among vascular-targeted therapiesCombining vasculature disrupting agent and Toll-like receptor 7/8 agonist for cancer therapy.New para-para stilbenophanes: synthesis by McMurry coupling, conformational analysis and inhibition of tubulin polymerisation.High-sensitivity in vivo imaging for tumors using a spectral up-conversion nanoparticle NaYF4: Yb3+, Er3+ in cooperation with a microtubulin inhibitor.An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate.Aminolevulinic acid-photodynamic therapy combined with topically applied vascular disrupting agent vadimezan leads to enhanced antitumor responsesLiposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma.Tumour targeting by microtubule-depolymerizing vascular disrupting agents.Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies.Diffusion-weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin a-4 phosphate after repeated administration
P2860
Q24606406-A94B48AB-EDF5-4C78-87F6-D4949035ABF0Q26781365-B6F6FEDF-7A91-4C23-BF8C-BB5F998F47A6Q28488869-2960FFE2-0014-4618-BF59-DA04C840295BQ30358185-22BA362E-5995-49F0-BBBE-8850D62BB74FQ33827457-5D743D2E-0BDD-4D03-81AA-2153DD8C0BC4Q34288315-0B29DC12-4ED5-4D79-92A7-11218DE9DCCBQ34954063-1CF3D7D6-97AC-4A89-A199-80DFDAE6AAC2Q35115922-A67D03BD-60DE-459C-9B75-1F7AB380EF56Q36943978-70BBF390-172B-4132-8284-CA70504D2258Q37008845-65AD0745-9785-4AEF-9F18-20E4E2EA6F4FQ37534993-91DCB16D-4C70-42E9-8243-514527B3A7C5Q41537813-DF134149-3AED-4E96-8F9D-8D2922F40684
P2860
Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Schedule dependence of combret ...... and spontaneous tumour models.
@en
Schedule dependence of combret ...... and spontaneous tumour models.
@nl
type
label
Schedule dependence of combret ...... and spontaneous tumour models.
@en
Schedule dependence of combret ...... and spontaneous tumour models.
@nl
prefLabel
Schedule dependence of combret ...... and spontaneous tumour models.
@en
Schedule dependence of combret ...... and spontaneous tumour models.
@nl
P2093
P2860
P356
P1476
Schedule dependence of combret ...... and spontaneous tumour models.
@en
P2093
David J Chaplin
Gemma Lewis
Gillian M Tozer
Sally A Hill
P2860
P356
10.1002/IJC.10655
P577
2002-11-01T00:00:00Z